PURPOSE/OBJECTIVE: Age and comorbidities could influence compliance to adjuvant Radiochemotherapy. We evaluate compliance and outcomes in elderly patients (.65 years old) with Glioblastoma Multiforme (GBM) treated according to three prospective phase II trials using Temozolomide (TMZ) concurrently and sequential to radiotherapy. MATERIALS AND METHODS: Three prospective phase II trials were performed for patients with a histological diagnosis of GBM (≥ 18 yrs); radiotherapy was delivered on tumor bed +/-residual + margin of 1,5 cm (CTV1: 59.4 Gy) and tumor bed +/-residual + edema until March 2008 or + margin of 3 cm (CTV2: 45 Gy) subsequently. The timing of concurrent Temozolomide (TMZ) was different between the studies: TMZ was administrated in the first and the last week of RT until December 2003 and every five days for week successively excluding Saturday and Sunday; in the third study patients received concomitant or sequential Fractionated Stereotactic Conformal RT boost to increase dose (69.4 Gy). Adjuvant TMZ was administered to all patients: six cycles if disease was absent, or until disease progression or unbearable toxicity in the other cases. Overall co-morbidities were assessed using the Charlson Index of Co-morbidity (CCI). Toxicity was evaluated according to RTOG; survival analisys was calculated using Kaplan-Meier method. RESULTS: 72 patients were treated between October 2001 to December 2012. Median age was 69 yrs (range 65-80 yrs): 41 male and 31 female. 41 patients underwent a partial removal and 31 a complete surgery. A CC1≥ 1 was present in 41% of patients. 66 patients received a total dose of 60 Gy, while six 69.4 Gy. The compliance to the treatment was 98%. Acute toxicity was reversible in all patients. Neutropenia was observed in in 16.6% (G1-2 11,1% and G3-G4 5,5%); thrombocytopenia was reported in 30,6% (G1-2 15,3% and G3-G4 15,3%). Neurologic toxicity was present in 30,6% of the patients without difference between G1-2 and G3-4. With a median follow-up of 72 months (range 6-139 months), median progression-free-survival was 12 months. Median overall survival (OS) was 15 months, 2-yrs OS was 30%, no patient being alive at 5 years. A significant impact on OS was been represented from only complete surgery vs partial (p ¼ 0.03) and a trend for radiation dose of 7000 vs 6000 cGy (p ¼ 0.06). It was not observe any difference in OS after a stratification of elderly (two subsets ≥ and ,70 yrs; three subsets ,70, between 70 and 74, .75 yrs). In particular, at 2 years OS was: 10% for patients .75 years old, 21% for .70 and ,74, 38% for , 70. CONCLUSIONS: This study suggests that radio-chemotherapy is feasible also in elderly with an improved OS for higher doses of RT. CCI ≤ 2 does not impact on compliance and outcomes. A prospective study is ongoing to confirm these findings.
